Skip to main content

Table 2 Associations of clinical variables with OS in METABRIC (total N = 1902)

From: Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy

   N % HR (95%CI) P
Radiotherapya No 765 59.78 1.000  
  Yes 1137 40.22 0.883(0.762,1.023) 0.097
Chemotherapy No 1506 79.18 1.000  
  Yes 396 20.82 1.158(0.930,1.44) 0.198
Agea < 60 841 44.22 1.000  
  ≥ 60 1061 55.78 1.988(1.736,2.276) < 0.001
Hormone therapy No 728 38.28 1.000  
  Yes 1174 61.72 0.942(0.808,1.099) 0.345
Surgery typea Conserving 755 40.14 1.000  
  Mastectomy 1126 59.86 0.773(0.664,0.901) 0.002
Laterality Left 935 52.03 1.000  
  Right 862 47.97 0.948(0.841,1.068) 0.394
Grade G1 164 8.96 1.000  
  G2 740 40.42 0.861(0.669,1.107) 0.623
  G3 927 50.63 0.904(0.785,1.41) 0.195
ER statusa Negative 444 23.34 1.000  
  Positive 1458 76.66 0.740(0.590,0.929) 0.010
PR status Negative 894 47.00 1.000  
  Positive 1008 53.00 0.948(0.820,1.097) 0.411
HER2a Negative 1666 87.59 1.000  
  Positive 236 12.41 1.322(1.076,1.624) 0.006
Menopausal status Peri 411 21.61 1.000  
  Post 1491 78.39 1.142(0.924,1.412) 0.254
Molecular subtypesa lumA 678 35.76 1.000  
  Claudin-low 198 10.44 0.854(0.650,1.121) 0.255
  her2 220 11.60 1.179(0.929,1.500) 0.176
  Basal 199 10.50 1.132(0.851,1.507) 0.395
  lumB 461 24.31 1.350(1.156,1.576) < 0.001
  Normal 140 7.38 1.263(0.983,1.621) 0.054
Tumor size (cm) a < 2 591 31.39 1.000  
  ≥ 2 1292 68.61 1.270(1.087,1.484) 0.003
Lymph nodesa 0 991 52.10 1.000  
   ≥ 1 911 47.90 1.363(1.161,1.600)  < 0.001
Pathological stagea I 478 34.09 0.798(0.660,0.965) 0.020
  II 800 57.06 1.000  
  III/IV 124 8.84 1.554( 1.274,1.895)  < 0.001
  1. aClinical variables that were left after fast backward multivariate COX regression